Use of digoxin in atrial fibrillation: One step further in the mortality controversy from the AFFIRM study.
Richard CharnigoPaul KhairyJing GuoAzadeh ShohoudiClaude-Samy ElayiPublished in: Pacing and clinical electrophysiology : PACE (2018)
Digoxin is associated with significantly increased mortality among AFFIRM patients collectively, as determined by MSM statistical methodology. However, the impact of digoxin among AFFIRM patients with coexisting HF is inconclusive.
Keyphrases
- atrial fibrillation
- cardiovascular events
- end stage renal disease
- ejection fraction
- newly diagnosed
- heart failure
- prognostic factors
- men who have sex with men
- type diabetes
- coronary artery disease
- left atrial appendage
- percutaneous coronary intervention
- left atrial
- hepatitis c virus
- patient reported outcomes
- catheter ablation
- acute coronary syndrome
- hiv infected
- human immunodeficiency virus